Baxalta Incorporated

Tweet this page
<
2015
>
Registration as it was on 21 Sep 2015
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

None declared

None declared

Lobbyists (Full time equivalent)

1 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Baxalta Incorporated   (Baxalta)

    EU Transparency Register

    725783918528-37 First registered on 04 Sep 2015

    Goals / Remit

    baxalta is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.

    Main EU files targeted

    All initiatives, policies, and legislative files related to the biopharmaceutical sector with particular focus on hematology, immunology and oncology . Topics include personalised medicines, orphan drugs, patient access to innovative medicines, R&D, clinical trials, HTA, biosimilars, pharmaceutical legislation, EU Falsified Medicines directive, Blood Directive.

    Address

    Head Office
    1200 Lakeside Drive
    Bannockburn, Illinois
    UNITED STATES
    EU Office
    boulevard d'Angleterre 2-4
    Braine l'Alleud
    BELGIUM
  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    50%1
    25%2

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 02 Mar 2024

    Name Start date End Date
    Mr Toon DIGNEFFE 28 Oct 2015 02 Sep 2016
    Ms Astrid Jankowitsch 28 Oct 2015 02 Sep 2016
    Ms Maria Joaquina RODRIGUEZ SANCHEZ 13 Oct 2015 02 Sep 2016
    Ms Joaquina Maria RODRIGUEZ SANCHEZ 10 Oct 2015 20 Oct 2015

    Complementary Information

    While several Baxalta employees contribute to the company’s activities falling under the scope of the Transparency Register, only 3 employees spend more than 10% of their respective work time on this: Toon Digneffe, Astrid Jankowitsch, Maria Rodriguez Sanchez

    Person in charge of EU relations

    Mr Toon Digneffe (Head of Patient and Innovation Policy)

    Person with legal responsibility

    Mr Ludwig N Hantson (CEO)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    EFPIA, EBE, Europabio, PPTA, Amcham EU, EBG

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    None declared

    Lobbying costs for closed financial year

    None declared

    Other financial info

    this amount is based on an estimate of costs for the period from July 1st, 2015 till December 31, 2015 as Baxalta started as an independent biopharmaceutical company as of July 1st, 2015. Information might be further updated to reflect the ongoing changes since the company creation on July 1st, 2015.
    In order to avoid double reporting, this figure does not include trade association memberships.
    The estimate has been done following the updated Transparency Register Implementation Guidelines and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

  • EU Structures

    Groups (European Commission)

    None

    ACC

    None

    Groups (European Parliament)

    None

    Communication activities

    The revision of the implementing guidelines on orphan drug designation; the follow-up actions of Council recommendations on an action in the field of rare diseases (2009/C 151/02); the setting-up of the European Commission initiative on rare cancers; the implementation of the Clinical Trials Regulation (536/2014); the debates and initiatives on international reference pricing of medicines; European cooperation mechanisms on Health Technology Assessment (eg EUnetHTA).

    Other activities

    Baxalta started as an independent biopharmaceutical company as of July 1st, 2015. Information might be further updated to reflect the ongoing changes since the company creation on July 1st, 2015.

  • Meetings

    Meetings

    None declared

Download this datacard